SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eikon Therapeutics Reports EIK1001 NSCLC Trial Results

Updated TeLuRide-005 results showed a 63.1% response rate and an 89.2% disease control rate for EIK1001 plus standard-of-care treatment.

EIKN

Story updates

10:04:11 AM UTC
SquawkNews
Eikon reported updated TeLuRide-005 data: EIK1001 plus pembrolizumab/chemo showed a 63.1% ORR and 89.2% DCR in 65 efficacy-evaluable NSCLC patients, with squamous ORR 72.4% and median DOR 12.9 months. Safety profile was generally consistent with standard of care.Material DetailsContext by AI Analys…

Related stories